Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study
- PMID: 32664100
- PMCID: PMC7360202
- DOI: 10.1097/MD.0000000000020966
Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis: A retrospective cohort study
Abstract
To investigate the effectiveness of dual filtration plasmapheresis (DFPP), a novel blood purification treatment, as a rapid and sustained disease-modifying therapy for active refractory rheumatoid arthritis (RA).A retrospective cohort study had been conducted. One hundred fifty three patients aged 18 years or older with active refractory RA were treated with DFPP combined with infliximab (IFX), IFX, or glucocorticoid (GC), all the above treatments were combined with methotrexate (MTX).Baseline characteristic of the 153 patients (DFPP: n = 53; IFX: n = 51; GC: n = 49) were similar across groups. The remission rate of CDAI (SDAI) in the DFPP treatment group was significantly higher than that of the IFX and GC group after 3 months of treatment. The remission rate of DFPP treatment group was above 50%, while in IFX and GC group, the rate of CDAI (SDAI) remission was 41.2% (37.3%) and 22.4% (14.2%) after 3 months of treatment.A combination of DFPP and biological agents can quickly induce remission or low disease activity of active refractory RA.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.J Rheumatol. 2012 Jun;39(6):1171-8. doi: 10.3899/jrheum.110978. Epub 2012 Apr 15. J Rheumatol. 2012. PMID: 22505700 Clinical Trial.
-
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.Clin Rheumatol. 2018 Apr;37(4):917-925. doi: 10.1007/s10067-017-3956-3. Epub 2018 Jan 8. Clin Rheumatol. 2018. PMID: 29313271 Clinical Trial.
-
A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.J Clin Rheumatol. 2007 Aug;13(4):193-8. doi: 10.1097/RHU.0b013e318124a483. J Clin Rheumatol. 2007. PMID: 17762452 Clinical Trial.
-
Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.Arthritis Rheumatol. 2017 Mar;69(3):518-528. doi: 10.1002/art.39945. Arthritis Rheumatol. 2017. PMID: 27696724
-
Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.Intern Med. 2020;59(16):1963-1970. doi: 10.2169/internalmedicine.3934-19. Epub 2020 Aug 15. Intern Med. 2020. PMID: 32801270 Free PMC article.
References
-
- Johnsson PM, Eberhardt K. Hand deformities are important signs of disease severity in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1398–401. - PubMed
-
- Boissier MC, Semerano L, Challah S, et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012;39:222–8. - PubMed
-
- Zhanguo L. Facing the challenge of low recognition and high status in rheumatoid arthritis. Natl Med J China 2009;89:1873–5. - PubMed
-
- Mishima M, Agishi T, Kaneko I, et al. Performance evaluation of conventional and modified double filtration plasmapheresis (DFPP). Trans Am Soc Artif Intern Organs 1984;30:665–70. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous